Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 30, 2008, Pages 10531-10536

  Veazey, Ronald S ^a   Ketas, Thomas A ^b   Klasse, Per Johan ^b   Davison, Donna K ^c   Singletary, Morgan ^a   Green, Linda C ^a   Greenberg, Michael L ^c   Moore, John P ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Trimeris Inc   (United States)

Author keywords

Entry inhibitors; Microbicide; SHIV challenge model

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR4; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; T 1249;

ARTICLE; CELL DIVISION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTI-INFECTIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MACACA; MODELS, GENETIC; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 48749094276     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0802666105     Document Type: Article

References (29)

1. Lederman MM, Offord RE, Hartley O (2006) Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 6:371-382.
2. Klasse PJ, Shattock R, Moore JP (2008) Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 59:455-471.
3. Klasse PJ, Shattock R, Moore JP (2006) Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 3:1501-1507.
4. van de Wijgert JH, Shattock RJ (2007) Vaginal microbicides: Moving ahead after an unexpected setback. AIDS 21:2369-2376.
5. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD (2006) Intravaginal ring delivery of the reverse transcriptase inhibitor TMC120 as an HIV microbicide. Int J Pharm 325:82-89.
6. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD (2005) Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56:954-956.
7. Lalezari JP, et al. (2005) T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 191:1155-1163.
8. Eron JJ, et al. (2004) Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 189:1075-1083.
9. Veazey RS, et al. (2005) Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102.
10. Tsai CC, et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20:11-18.
11. Lederman MM, et al. (2004) Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306:485-487.
12. Zhang Y, et al. (2000) Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J Virol 74:6893-6910.
13. + T cells, and AIDS. J Virol 71:4016-4023.
14. Harouse JM, et al. (2001) Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75:1990-1995.
15. Moore JP, Kitchen SG, Pugach P, Zack JA (2004) The CCR5 and CXCR4 coreceptors: Central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 20:111-126.
16. Margolis L, Shattock R (2006) Selective transmission of CCR5-utilizing HIV-1: The "gatekeeper" problem resolved? Nat Rev Microbiol 4:312-317.
17. Yi Y, et al. (2008) Entry coreceptor use and fusion inhibitor T20 sensitivity. J Acquir Immune Defic Syndr 47:285-292.
18. Yi Y, Shaheen F, Collman RG. (2005) Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol 79:1480-1486.
19. Veazey RS, et al. (2003) Use of a small-molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian/human immunodeficiency virus infection. J Exp Med 198:1551-1562.
20. Ketas TJ, et al. (2007) Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes. Virology 364:431-440.
21. Haase AT (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5:783-792.
22. Veazey RS, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343-346.
23. Guo Q, et al. (2003) Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J Virol 77:10528-10536.
24. Hatse S, et al. (2005) AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 70:752-761.
25. Veazey RS, et al. (2005) Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11:1293-1294.
26. Kimpton J, Emerman M (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 66:2232-2239.
27. Hu QX, et al. (2000) Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J Virol 74:11858-11872.
28. Zwick MB, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905.
29. Coakley E, Petropoulos CJ, Whitcomb JM (2005) Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 18:9-15.